InsidersTradesSigma
Follow the Oncorus, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Oncorus, Inc. has recorded 19 insider filings. The latest transaction was filed on 30 December 2022 (Cession). Among the most active insiders: Flynn James E. The full history is free.
19
Insider Decl.
n/a
Thresholds
€97,235
5 ops.
Buy Volume
€512,351
11 ops.
Sell Volume
31Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 30 December 2022
Declarations19 total
24,757 shares@ US$0.2515.7% of flowCommon StockSEC:0001193805-22-001817:0
28,977 shares@ US$0.2719.8% of flowCommon StockSEC:0001193805-22-001793:4
3,692 shares@ US$0.282.6% of flowCommon StockSEC:0001193805-22-001793:0
909 shares@ US$0.280.6% of flowCommon StockSEC:0001193805-22-001793:2
28,977 shares@ US$0.2719.8% of flowCommon StockSEC:0001193805-22-001793:3
7,136 shares@ US$0.274.9% of flowCommon StockSEC:0001193805-22-001793:5
3,693 shares@ US$0.282.6% of flowCommon StockSEC:0001193805-22-001793:1
44,394 shares@ US$0.2932.8% of flowCommon StockSEC:0001193805-22-001764:0
934 shares@ US$0.411.0% of flowCommon StockSEC:0001193805-22-001734:0
3,777 shares@ US$1.2020.5% of flowCommon StockSEC:0001209191-22-031907:0
Canonical exit: 23 Aug 2022 (T+90)
1,610 shares@ US$1.208.8% of flowCommon StockSEC:0001209191-22-031614:0
Canonical exit: 18 Aug 2022 (T+90)
1 shares@ US$1.200.0% of flowCommon StockSEC:0001209191-22-030495:0
Canonical exit: 15 Aug 2022 (T+90)
14,094 shares@ US$1.0870.7% of flowCommon StockSEC:0001209191-22-029259:0
Canonical exit: 10 Aug 2022 (T+90)
32,500 shares@ US$1.8121.6% of flowCommon StockSEC:0001209191-21-066003:0
15,000 shares@ US$5.79750.0% of flowCommon StockSEC:0001209191-21-065058:0
Canonical exit: 14 Feb 2022 (T+90)
43,707 shares@ US$1.8128.4% of flowCommon StockSEC:0001209191-21-061525:0
12,899 shares@ US$16.6933.4% of flowCommon StockSEC:0001209191-21-037764:0
35,561 shares@ US$1.8110.0% of flowCommon StockSEC:0001209191-21-035931:0
22,755 shares@ US$15.9456.6% of flowCommon StockSEC:0001209191-21-029987:0
19 of 19 declarations
关于 Oncorus, Inc.
Oncorus, Inc. (股票代码: ONCR) 是一家总部位于美国、在美国纳斯达克市场上市的生物技术公司。对于法国、比利时和瑞士的投资者来说，Oncorus 最好被理解为一家处于早期阶段、专注于开发的生物技术公司，而非一家产生收入的商业医疗保健公司。该公司最初围绕肿瘤创新而建立，重点是基因和免疫疗法方法，后来将其战略缩小，优先发展静脉注射的自扩增 RNA 药物，旨在治疗癌症。([nasdaq.com](https://www.nasdaq.com/press-release/oncorus-announces-portfolio-reprioritization-to-focus-on-iv-administered-self?utm_source=openai)) 在运营方面，Oncorus 仍然是一个研发故事。其核心业务线是临床前和临床开发、平台验证和产品组合推进，而不是制造规模或广泛的商业销售。公开披露表明，该公司重新调整了其管线优先级，以专注于其领先的基于 RNA 的项目，而其他项目的进展则取决于增量融资或战略合作。这使得投资案例高度事件驱动：估值主要由数据公布、资金储备和合作潜力驱动。([nasdaq.com](https://www.nasdaq.com/press-release/oncorus-announces-portfolio-reprioritization-to-focus-on-iv-administered-self?utm_source=openai)) 在竞争方面，Oncorus 在生物技术领域最拥挤和资本最密集的领域之一运营。它与大型制药集团、资金充足的 RNA 平台以及追求类似机制或治疗领域的肿瘤学生物技术公司间接竞争。其主要区别在于自扩增 RNA 平台以及通过静脉注射实现全身性抗癌活性的潜力。如果科学能够转化为临床，这可能会带来显著的上升空间；然而，该公司也面临着巨大的执行、监管和融资风险，这对于一家商业化前的生物技术公司来说是典型的。([nasdaq.com](https://www.nasdaq.com/press-release/oncorus-announces-portfolio-reprioritization-to-focus-on-iv-administered-self?utm_source=openai)) 从地理位置上看，Oncorus 是一家美国公司，其业务与波士顿地区的生命科学集群相关。公开公告显示其总部迁至马萨诸塞州剑桥，后来的备案和发布提及马萨诸塞州安多弗，表明其在更广泛的马萨诸塞州生物技术走廊中占有一席之地。这个位置具有战略意义，因为它提供了获取科学人才、研究基础设施、投资者和潜在合作伙伴的途径。([nasdaq.com](https://www.nasdaq.com/press-release/oncorus-announces-debt-capital-facility-with-k2-healthventures-with-%2420-million?utm_source=openai)) 最近的里程碑事件集中在产品组合的重新优先排序和资本管理上。该公司于2022年宣布了一项重大的战略调整，以专注于静脉注射的自扩增 RNA 药物，后来的披露表明，非核心项目的进一步开发将需要额外的融资或战略支持。对于分析 SEC Form 4 内部交易的投资者来说，主要结论是，内部人活动应在一家小型临床生物技术公司的背景下解读，其近期价值更多地取决于科学里程碑和资金可见性，而不是传统的经营业绩。([nasdaq.com](https://www.nasdaq.com/press-release/oncorus-announces-portfolio-reprioritization-to-focus-on-iv-administered-self?utm_source=openai))
